These results are concordant with those of Teratani et al [10], who recently reported enhanced AEBP1 expression in liver tissue from NASH patients (N = 44) compared to individuals with NAFLD (N = 16) and metastatic liver cancer patients with no evidence of steatosis, inflammation, or fibrosis (N = 14). The gene discussed is AEBP1; the disease is metabolic dysfunction-associated steatohepatitis.